朱理辉,霍继荣,张琍,李国庆,廖文秋

• 1:南华大学附属第二医院消化内科
• 2:中南大学湘雅二医院消化内科

摘要(Abstract)：

目的探讨树突状细胞联合细胞因子诱导的杀伤细胞(dendritic cell-cytokine induced killer cell,DCCIK)过继性免疫治疗联合肝动脉化疗栓塞术(transcatheter arterial chemoembolization,TACE)治疗原发性肝癌的临床疗效及安全性分析。方法 105例原发性肝癌患者分成两组,TACE组58例,DC-CIK联合TACE组47例。TACE组行≥1次TACE,DC-CIK联合TACE组在TACE的间歇期给予≥1次的DC-CIK治疗,分析2种方法在中位生存期、肝功能及甲胎蛋白定量、安全性等方面的差异及对影响疗效的相关因素进行分析。结果 DC-CIK联合TACE组的中位生存期高于TACE组(18月vs 12月),差异有统计学意义﹙P<0.05﹚。单因素分析得出患者巴塞罗那临床肝癌分组方案(Barcelona clinic liver cancer,BCLC)、Child-Pugh分级、门静脉癌栓和是否联合应用DC-CIK治疗是影响肝癌患者总的中位生存期的因素(P<0.05)。多因素分析得出BCLC分期、Child-Pugh分级、甲胎蛋白(alpha feto protein,AFP)定量是影响DC-CIK联合TACE组总生存期的危险因素。治疗后3月观察两组的AFP均下降,肝功能好转,DC-CIK联合TACE组更明显,差异有统计学意义﹙均P<0.05﹚。DC-CIK治疗后只有2例次发热,1例次皮疹,经对症处理后患者无不适感。结论 DC-CIK联合TACE治疗原发性肝癌能延长中位生存期,改善肝功能,降低AFP,且安全可靠;术前分析BCLC分期、Child-Pugh分级、AFP定量等因素对预测疗效有指导意义。

关键词(KeyWords)： 肝肿瘤/治疗;肝动脉/外科学;化学栓塞,治疗性/方法;免疫疗法,过继;杀伤细胞,淋巴因子激活/免疫学;树突细胞/免疫学;治疗结果

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 朱理辉,霍继荣,张琍,李国庆,廖文秋

DOI: 10.13267/j.cnki.syzlzz.2016.02.019

参考文献(References)：

• [1]Llovet JM,Ricci S,Mazzaferro V,et al.Sorafnib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359(4):378-390.
• [2]Morimoto M,Numata K,Kondo M,et al.Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib[J].Hepatol Res,2011,41(4):296-302.
• [3]陈宝安,李曼,孙载阳,等.DC与CIK共同培养对肝癌细胞杀伤活性的研究[J].临床医学,2010,30(1):16-18.
• [4]Rutella S,Iudicone P,Bonanno G,et al.Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol[J].Cytotherapy,2012,17(4):841-850.
• [5]Thanendrarajan S,Kim Y,Schmidt-Wolf I.New adoptive immuntherapy strategies for solid tumours with CIK cells[J].Expert Opin Biol Ther,2012,12(5):565-572.
• [6]中华人民共和国卫生部.原发性肝癌诊疗规范(2011版)[J].临床肝胆病杂志,2011,27(11):1141-1159.
• [7]Miyayama S,Yamashiro M,Okuda M,et al.The march of extrachepatic collaterals annalysis of callaterals analysis of blood supply to hepatocellular carcinoma located in the barearea of the liver after chemoembolization[J].Cardiovasc Intervent Radio,2010,3(3):513-522.
• [8]Xiao EH,Guo D,Bian DJ,et al.Effect of precperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells[J].World J Gastroenterol,2009,15(36):4582-4586.
• [9]Hui D,Qiang L,Jian W,et al.A randomized,controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma[J].Dig Liver Dis,2009,41(1):36-41.
• [10]Jakel CE,Schmidt-Wolf IG.An update on new adoptiveimmunotherapy strategies for solid tumors with cytokineinduced killer cells[J].Expert Opin Biol Ther,2014,14(7):905-916.
• [11]Hao MZ,Lin HL,Chen Q,et al.Efficacy of transcatheter arterial chemoembolization combined with cytokine-induced killer cell therapy on hepatocellular carcinoma a comparative study[J].Chin J Cancer,2010,29(2):172
• [12]盛燕军.原发性肝癌患者血清AFP、CEA、CA199水平变化的特异度、敏感度分析[J].浙江中医药大学学报,2014,38(6):746-748.
• [13]Willmsky G,Protzer U,Knolle P,et al.Adoptive T-cell therapy to treat liver cancer is the liver microenvironment key[J]?Oncotarget,2013,4(8):1117-1118.
• [14]蒋琦,徐增辉,王颖,等.晚期非小细胞肺癌患者DC-CIK治疗前的免疫状态与预后的关系[J].实用肿瘤杂志,2015,30(2):122-126.
• [15]李娜,薄常文,马文华,等.过继免疫细胞治疗对原发性肝癌患者免疫学指标的影响[J].中国现代医学杂志,2015,25(21):31-34.
• [16]Cui Y,Yang X,Zhu W.Immune response clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients[J].Oncol Lett,2013,6(2):537-541.